Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025

ACADIA PHARMACEUTICALS INC

2025-Q1 EPS reported $0.11 revenue$244,317,000

Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)
Net income $19.0M ($0.11/sh) vs $16.6M ($0.10/sh) in Q1 2024; cash $681.6M
DAYBUE record 954 unique patients shipped; 30% field force expansion completed; first EU patient served
COMPASS PWS Phase 3 topline results now expected early Q4 2025 (accelerated); if positive, NDA submission Q1 2026
2025 guidance reiterated: total rev $1.03-1.095B; R&D expense raised to $330-350M due to study acceleration

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.